Immunome buys desmoid tumor asset; UK looks into Thermo Fisher-Olink deal; Kyverna’s upsized IPO

Plus, news about Attralus, Sangamo, Mithra, NeOnc, 4D Molecular Therapeutics and Immix Biopharma:

Immunome buys Ayala’s desmoid tumor asset: The biotech will pay $20 million in cash and $30 million in stock to Ayala, with another $37.5 million in milestones. The oral treatment candidate is a…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks